A number of
key players are competing against each other to
expand their existing customer base in the insulin delivery devices market. In
2015, the global insulin delivery devices market was dominated by Becton, Dickinson
and Company (U.S.), Medtronic plc (Ireland), Novo Nordisk A/S (Denmark), Sanofi
(France), and Eli Lilly and Company (U.S.).
Browse
100 market data tables and 38 figures spread through 149 pages and in-depth TOC
on "Insulin
Delivery Devices Market.
In
2015, Novo Nordisk A/S accounted for a share of ~46% in the global insulin pens
market. To maintain its leadership position,
the company focuses on product launches as its key growth strategy. In the field of insulin delivery devices,
the company offers insulin pens (NovoPen, NovoPen Echo, NovoTouch, FlexPen,
InnoLet, and PenMate) and pen needles (NovoFine, NovoTwist, and NovoFine
Autocover).
The company has its distribution and production facilities in more than 75
countries and markets its products in more than 180 countries. Novo Nordisk has
strategically placed its facilities across five continents with 16 production
sites. With an aim to build a sustainable market position, the company offers a
dedicated program named “Changing Diabetes” through which it supplies free
insulin to more than 14,000 children. As of 2016, the company established 108
clinics and trained more than 7,000 health professionals.
In 2015, Becton, Dickinson and Company dominated the pen needles market with a
market share of ~53%. To maintain
its position, the company has adopted growth
strategies such as product enhancements, geographical expansions, and product
launches. In September 2014, BD launched its Autoshield Duo Pen Needle in the
U.S. BD markets its products through independent distribution channels and
directly to end users by independent sales representatives. The company sources
raw materials from multiple vendors which ensure continuous supply and
uninterrupted production and time delivery. The company has a strong focus on
R&D activities. A majority of its R&D is
conducted in the U.S. Moreover, BD also collaborates with universities,
medical centers, and other entities to conduct R&D programs, and retains
individual consultants to support its efforts in specialized fields.
Download PDF Brochure: - http://www.marketsandmarkets.com/pdfdownload.asp?id=107632092
In
2015, Medtronic plc accounted for a share of ~82% in the global insulin pumps
market. The company adopted both organic as well as inorganic growth strategies to strengthen its
position in the insulin delivery devices market. Medtronic
sells its products through direct sales representatives in the U.S. and through
a combination of distributors and direct sales representatives outside the U.S.
The company has manufacturing facilities at its 89 sites and serves hospitals,
physicians, clinicians, and patients in approximately 160 countries worldwide. The company also focuses on
alliances and partnerships to enhance its market share.
No comments:
Post a Comment